For example, TAA-AAbs against fumarate hydratase FH (FH-AAbs) frequently occur in malignant thyroid tumors while being absent from cancer-free controls; however, benign and malignant thyroid neoplasms demonstrate quite comparable frequencies of FH-TAAbs (Figure 2), thus precluding their use in any setting that requires discrimination between benign and malignant entities. The gene discussed is FH; the disease is thyroid cancer.